Spine Market Shares (2Q10) / Source: PearlDiver Technologies Inc.
Medtronic lost 4.7% of market share in spine this last quarter. Revenue declined over 9%. What happened? The company’s CEO Bill Hawkins acknowledged the pain and said people won’t defer procedures forever and Medtronic will be back. How will they do it? Read here.
GSDF parachute/Wikimedia Commons
The large joint reconstruction market slowed following two quarters of strong growth. Read on to find out how both foreign and domestic sales descended back toward the ground level.
Wikimedia Commons
Who will control one of the oldest suppliers of allograft products in U.S. medicine? Apparently Medtronic. Just as a dissident group of shareholders was about to force a decision about Osteotech’s future and control, Medtronic arrives like a white knight, pays 65% premium, and takes the company. Why?
Orthofix's North American Operations and Education Center, Lewisville, Texas/Orthofix
For Orthofix, turning 30 is definitely cause for celebration. The device company is enjoying great profits, a new state-of-the-art facility and the release of fresh products. Sometimes getting older can be a good thing.
Image source: morgueFile.com
The debate over whether the orthopedics industry is in for a difficult short term versus a more favorable long term based on demographically driven demand is an important one. Here is one way to frame up this debate and get an idea of where we’re heading.
Eric Major, CEO, K2M
Welsh, Carson, Anderson & Stowe (WCAS)—the largest and most successful private equity firm focused on information/business services and health care—just laid a big bet on spine and selected the Virginia-based upstart K2M as its platform company. Smart money.
an argument / morgueFile.com
Zimmer and one of its physician/consultants had a very public divorce over differences regarding the company’s NexGen knee. The New York Times printed the physician’s side. This week we offer the company’s response. What’s needed to avoid these situations in the future? Read on..